The last decade of Italian pharmaceutical policy: Instability or consolidation?

PharmacoEconomics

Volumn 26, Issue 1, 2008, Pages 5-15

  Fattore, Giovanni ^a   Jommi, Claudio ^a,b  

^a BOCCONI UNIVERSITY   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Decision making; Formularies; Health policy; Pharmaceutical services; Pricing; Reimbursement; Research and development

Indexed keywords

GENERIC DRUG;

COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; INSTITUTIONAL CARE; ITALY; LEADERSHIP; MEDICAL DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REIMBURSEMENT; REVIEW;

EID: 37549030856     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826010-00002     Document Type: Review

References (34)

1. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage 2005; 20 (4): 291-306
2. Jommi C. Pharmaceutical policy and organisation of the regulatory authorities in the main EU countries. Milan: Egea, 2001
3. Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Policy 1998; 46 (1): 21-41
4. AIFA (Agenzia Italiana del Farmaco). L'uso dei farmaci in Italia: rapporto nazionale, Anno 2006. Rome: Ministero della Salute, 2007
5. Osservatorio Farmaci, CERGAS, Bocconi University. Report 19. Report annuale per il 2006. Milan: Bocconi University, 2006
6. Fattore G. Cost-containment and reforms in the Italian National Health Service. In: Mossialos E, Le Grand J, editors. Health care and cost containment in the European Union. Aldershot: Ashgate, 1999: 513-46
7. Jommi C, Cantù E, Anessi Pessina E. New funding arrangements in the Italian National Health Service. Int J Health Plann Manage 2001; 6 (4): 347-68
8. Anessi Pessina E, Jommi C, Cantù E. Phasing out market mechanisms in the Italian NHS. Public Money Manage 2004; 24 (5): 309-16
9. France G, Taroni F. The evolution of health-policy making in Italy. J Health Polit Policy Law 2005; 30 (1-2): 169-87
10. Anessi Pessina E, Cantu E. Whither managerialism in the Italian National Health Service? Int J Health Plann Manage 2006; 21 (4): 327-55
11. Cavallo MC, Gerzeli S, Vendramini E. Organizzazione e gestione delle cure primarie: un'indagine nazionale. Milan: McGraw Hill, 2001
12. Mapelli V, Lucioni C. Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value Health 2003; 6 Suppl. 1: S31-45
13. Garattini S. Cultural shift in Italy's drug policy. Lancet 1995; 346 (8966): 5-6
14. Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int J Health Plann Manage 2005; 20 (4): 375-98
15. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20 (4): 307-28
16. Busse R, Schreÿogg J, Henke KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage 2005; 20 (4): 329-49
17. De Wolf P, Brouwer WBF, Rutten FFH. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs? Int J Health Plann Manage 2005; 20 (4): 351-74
18. Gerzeli S, Jommi C, Villa S. Politiche regionali e variabilità delle spesa farmaceutica convenzionata. Economia Pubblica 2003; 33 (5): 93-129
19. Jommi C, Fattore G. Regionalization and drugs cost-sharing in the Italian NHS. Eur Observer 2003; 3: 1-4
20. Damiani G, Federico B, Oradei M, et al. Impact of drug policy on the use of parenteral cephalosporin in Italy. Pharm World Sci 2002; 24 (5): 169-71
21. Formoso G, Liberati A, Magrini N. Practice guidelines: useful and participative method? Survey of Italian physicians by professional setting. Arch Intern Med 2001; 161 (21): 2037-42
22. Fattore G, Torbica A. Inpatient reimbursement system in Italy: how do tariffs relate to costs? Health Care Manage Sci 2006; 9 (3): 251-8
23. Mapelli V. Cost-containment measures in the Italian healthcare system. Pharmacoeconomics 1995; 8 (2): 85-90
24. Brenna A, Grassi M, Lucioni C. L'effetto del ticket moderateur sui farmaci: presupposti economici ed analisi statistica. Pavia: La Goliardica Pavese, 1984
25. Hanau C, Rizzi D. Econometria dei provvedimenti pubblici sull'assistenza farmaceutica: il caso dell'Emilia Romagna. Economia Pubblica 1986; 3: 177-83
26. Anessi Pessina E. The effect of user charges on the utilisation of prescription medicines in the Italian National Health Service [dissertation]. Ann Arbor (MI): UMI Dissertation Services, 1997
27. Atella V, Schafheutle E, Noyce P, et al. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy 2005; 4 (1): 23-35
28. Association of European Self-Medication Industry (AESGP). Economic and legal framework for non-prescription medicines. Brussels: AESGP, 2006
29. Associazione Nazionale delle Imprese Farmaceutiche di Automedicazione (ANIFA). Numeri e indici dell'automedicazione. Milan: Anifa, 2006
30. Jommi C. Italy: past reforms and future prospects. Eurohealth 2001; 2: 11-3
31. Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005; 72 (1): 53-63
32. Garattini L, Ghislandi S. Off-patent drugs in Italy: a short-sighted view? Eur J Health Econ 2006; 7 (1): 79-83
33. Istat (Istituto Nazionale di Statistica) website [online]. Available from URL: http://www.istat.it [Accessed 2007 May 15]
34. Jommi C, Paruzzolo S. Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case study. Health Policy 2007; 81: 117-30